Sign inCreate account

Report workspace tools

NCT05194592UNKNOWNanonymous

Comparison of the Effects of Dapagliflozin and Gemigliptin on Ketone Metabolism and Cardiac Remodeling in Type 2 Diabetes

Sponsor

Source record

Wonju Severance Christian Hospital

Phase

Source record

PHASE4

Modality

AI-normalized

small molecule

Target

AI-normalized

Dapagliflozin, Gemigliptin

Indication / condition

AI-normalized

Type2 Diabetes

Intervention

Source record

Dapagliflozin, Gemigliptin

Source & freshness

Source record

NCT ID

NCT05194592

Original source

ClinicalTrials.gov

Source last updated

Aug 01, 2023

Ingested at

Jun 08, 2026

Internal sync

Jun 08, 2026

Model version

trialsignal-ai-v1

Normalized confidence

96%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT05194592

Title

Comparison of the Effects of Dapagliflozin and Gemigliptin on Ketone Metabolism and Cardiac Remodeling in Type 2 Diabetes

Sponsor

Wonju Severance Christian Hospital

Status

UNKNOWN

Phase

PHASE4

Condition raw

Type2 Diabetes, Remodeling, Ventricular

Condition normalized

Type2 Diabetes, Remodeling, Ventricular

Modality raw

small molecule

Modality normalized

small molecule

Target raw

Dapagliflozin, Gemigliptin

Target normalized

Dapagliflozin, Gemigliptin

Interventions

Dapagliflozin, Gemigliptin

Public preview

Source record

Comparison of the Effects of Dapagliflozin and Gemigliptin on Ketone Metabolism and Cardiac Remodeling in Type 2 Diabetes is a PHASE4 clinical asset sponsored by Wonju Severance Christian Hospital in Type2 Diabetes, Remodeling, Ventricular. SEO and diligence focus: Dapagliflozin, Gemigliptin, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

Comparison of the Effects of Dapagliflozin and Gemigliptin on Ketone Metabolism and Cardiac Remodeling in Type 2 Diabetes

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 13, 2026

NCT ID

NCT05194592

Status

UNKNOWN

Phase

PHASE4

Sponsor

Wonju Severance Christian Hospital

Executive brief

Investment-Ready Snapshot

Comparison of the Effects of Dapagliflozin and Gemigliptin on Ketone Metabolism and Cardiac Remodeling in Type 2 Diabetes is a PHASE4 clinical asset sponsored by Wonju Severance Christian Hospital in Type2 Diabetes, Remodeling, Ventricular. SEO and diligence focus: Dapagliflozin, Gemigliptin, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedAug 01, 2023
Internal syncJun 08, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT05194592

Indication

Type2 Diabetes

Modality

small molecule

Target

Dapagliflozin, Gemigliptin

Intervention

Dapagliflozin, Gemigliptin

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.